Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) -

- Priced oversubscribed $40 million underwritten registered direct offering with participation from new and existing healthcare dedicated investors - 

Read more at globenewswire.com